Drug maker Novo Nordisk says semaglutide, the active ingredient for the weight loss jab Wegovy, does not slow Alzheimer's -- despite initial hopes that it might help against dementia. From a report: Researchers began two large trials involving more than 3,800 people after reports the medicine was having an impact in the real world. But the studies showed the GLP-1 drug, which is already used to manage type 2 diabetes and obesity, made no difference compared to a dummy drug. The disappointing results are due to be presented at an Alzheimer's disease conference next month and are yet to be published in a peer-reviewed journal.
Read more of this story at Slashdot.